Ixekizumab vs Rituximab
Ixekizumab vs Rituximab: Overview
This comparison examines the pharmacological differences between Ixekizumab and Rituximab.
Mechanism of Action
Rituximab: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.
Pharmacokinetics
Half-life: Rituximab β 22 days.
Chemical Properties
Type: Ixekizumab β Antibody; Rituximab β Antibody.